Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Blood|June 5, 2015
Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trialDavide Gianfreda, Maria Nicastro, Maricla Galetti, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancerMarcello Tiseo, Marzia Capelletti, Giuseppe De Palma, et al.Molecular Cancer|November 25, 2011
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell linesRoberta R Alfieri, Maricla Galetti, Stefano Tramonti, et al.Cancer Letters|April 10, 2012
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clonesAndrea Cavazzoni, Mara A Bonelli, Claudia Fumarola, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating MutationSilvia La Monica, Denise Madeddu, Marcello Tiseo, et al.Molecular Cancer Therapeutics|May 28, 2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene AlterationsMara A Bonelli, Andrea Cavazzoni, Francesca Saccani, et al.Breast Cancer Research and Treatment|January 8, 2010
Synergistic activity of letrozole and sorafenib on breast cancer cellsMara A Bonelli, Claudia Fumarola, Roberta R Alfieri, et al.Scientific Reports|March 19, 2024
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell modelsSilvia La Monica, Federica Vacondio, Kamal Eltayeb, et al.Journal of Experimental & Clinical Cancer Research : CR|May 30, 2019
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Minari, Daniele Cretella, et al.Molecular Cancer|December 14, 2012
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell linesAndrea Cavazzoni, Roberta R Alfieri, Daniele Cretella, et al.Pageof 6